Skip to main content



Clinical Trial Shows More Updated COVID Boosters Likely Needed

Thursday, April 20, 2023

The trial, led by Angela Branche, M.D., Co-Director, URMC Vaccine and Treatment Evaluation Unit, demonstrated that current COVID boosters elicit weak immune responses to the newest COVID variants, suggesting a need to continue monitoring for new variants and possibly developing new boosters to better protect against them.

Read the full story

Race to RSV Vaccine Approval: URMC Researchers Leading the Way

Wednesday, April 5, 2023

URMC scientists are at the center of vaccine development for RSV in older adults, leading a phase 3 clinical trial of a vaccine that is detailed in a new study just released in the New England Journal of Medicine. The study, led by Edward Walsh, MD, professor of medicine, and co-authored by Ann Falsey, MD, professor of medicine and co-director of the UR Vaccine Treatment and Evaluation Unit, covers phase 3 clinical trial results of the Pfizer RSV vaccine that showed promising results. This data has been presented to the FDA for review. Walsh and Falsey are involved in multiple trials for RSV vaccine development, positioning URMC as a research center of choice for companies like Pfizer.

Read the full story

Ann Falsey's Study Shows 80 Percent Effectiveness of RSV Vaccine for Older Adults

Thursday, February 16, 2023

Ann Falsey, M.D., professor of Medicine in infectious diseases and co-director of the URMC Vaccine and Treatment Evaluation Unit, is lead author of a recent New England Journal of Medicine paper based on a phase 2b clinical trial of the Janssen adult RSV vaccine. Falsey's research is among the first breakthroughs toward a safe and effective vaccine. With these results, Janssen has initiated its phase 3 trials with Falsey in an advisory role.

Read the full article (subscription required).